Trade Galectin Therapeutics Inc. - GALT CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.03
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022179 %(-$0.44)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.02218%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000043 %(-$0.00)Trade size with leverage ~ $2,000.00Money from leverage ~ $$1,000.00Go to platform: -0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 50.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022179 %
  (-$0.44)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000043 %
  (-$0.00)

Key Stats

• Prev. Close: 3.6154
• Open: 3.5954
• 1-Year Change: -23.09%
• Day's Range: 3.5954 - 3.945

Trade Galectin Therapeutics Inc. - GALT

About Galectin Therapeutics Inc

Galectin Therapeutics Inc. is a biotechnology company that is focused on developing novel therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s product candidates include galectin-3 inhibitor, belapectin (GR-MD-02) and GM-CT-01. The Company’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases. The Company is using a galectin-3 inhibitor to treat advanced liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients. The Company also designed a Phase IIb/II clinical study, the NAVIGATE trial, evaluating the safety and efficacy of its galectin-3 inhibitor, belapectin (GR-MD-02), for the prevention of esophageal varices in patients with non-alcoholic steatohepatitis (NASH) cirrhosis.

Financial summary

BRIEF: For the nine months ended 30 September 2021, Galectin Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased 49% to $23.4M. Higher net loss reflects Research and development increase of 58% to $17.7M (expense), Other General and administrative increase of 15% to $3.6M (expense), Stock-based Compensation in SGA increase of 38% to $1.2M (expense).

Equity composition

Common Stock $.001 Par, 03/12, 300M auth., 12,842,850 issd. Insiders own 18.44%. Ser. A Pref. Stock 5M auth., 1,592,500 issd. Redeemable convt. Pref. stock Ser. B-1 900,000 auth., 900,000 issd. Ser. B-2 2.1M auth., 2,100,000 issd. PO 12/13/01, 1,428,572 shares @ $3.50by Atlas Capital Services LLC. 03/12. 1-for-6 Reverse split.